Lovastatin inhibits erythroleukemia progression through KLF2-mediated suppression of MAPK/ERK signaling

Jian Gao(China Pharmaceutical University), Yaacov Ben‐David(Guiyang Medical University)
BMC Cancer
April 4, 2023
Cited by 9


Related Papers